JDMAX | JGRCX | JDMAX / JGRCX | |
Total Expense Ratio | 1.14 | 1.74 | 66% |
Annual Report Gross Expense Ratio | 1.14 | 1.74 | 66% |
Fund Existence | 16 years | 16 years | - |
Gain YTD | 4.498 | 4.179 | 108% |
Front Load | 6% | N/A | - |
Min. Initial Investment | 2500 | 2500 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 22.2B | 22.2B | 100% |
Annual Yield % from dividends | 0.76 | 0.28 | 274% |
Returns for 1 year | 7.20 | 5.44 | 132% |
Returns for 3 years | 15.54 | 9.23 | 168% |
Returns for 5 years | 9.13 | -0.69 | -1,322% |
Returns for 10 years | 55.98 | 35.97 | 156% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
BAFE | 26.65 | 0.24 | +0.91% |
Brown Advisory Flexible Equity ETF | |||
RWL | 105.59 | 0.63 | +0.60% |
Invesco S&P 500 Revenue ETF | |||
IHE | 66.58 | -0.01 | -0.02% |
iShares US Pharmaceuticals ETF | |||
SPC | 21.43 | -0.03 | -0.16% |
CrossingBridge Pre-Merger SPAC ETF | |||
BMN | 24.74 | -0.08 | -0.32% |
BlackRock 2037 Municipal Target Term Trust |